Davis Polk is advising Roche in connection with its $8.3 billion acquisition of InterMune, Inc. The closing of the transaction is expected to take place in 2014.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused health care with combined strengths in pharmaceuticals and diagnostics. InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.
The Davis Polk corporate team includes partners Arthur F. Golden and Marc O. Williams, and associates Lee Hochbaum, Brian J. Snyder and Zain Ur Rehman. Partners Jean M. McLoughlin and Edmond T. FitzGerald, and associate Gillian Emmett Moldowan are providing executive compensation advice. Partner Ronan P. Harty is providing antitrust and competition advice. Partner Michael Mollerus is providing tax advice. All members of the Davis Polk team are based in the New York office.
